Brane seeks €8M for Parkinson’s and pain drugs

Investment opportunity

The new pharmaceutical spin-out company, Brane Discovery Srl, is seeking €8 million for its drug development addressing Parkinson’s disease and neuropathic pain. 

Brane is about to start its first financing campaign to raise around €8 million.  The investment would be used to progress two projects up to clinical proof-of-concept, before seeking licensing partners.  BND-001 is an NCE developed for Parkinson's Disease while BND-003 is a pyrrolidinone derivative for Neuropathic Pain.  Both are planned to enter the clinic in 2008.

Brane also has a programme developing v-ATPase inhibitors (BND-002), addressing cancer and other indications, for which it is now seeking licensing or co-development partners. Brane also has a running discovery programme with a number of CNS Exploratory Projects undergoing early validation.

“We’re interested to discuss about co-development, or even out-licensing, for BND-002 in oncology, as this is not the main therapeutic area for Brane in future,” said Brane spokesman, Mr. Pierfausto. “We’re also ready to consider partnership for our CNS projects, although this is not strictly needed at this time; we’d look for people with clinical / commercial experience in Parkinson’s disease or in neuropathic pain, i.e. the therapeutic areas for our projects.”

Brane is a private specialty pharmaceutical company focused on the development of novel CNS therapies. The company is based in Milan, Italy and has a portfolio of preclinical products addressing Parkinson's disease, neuropathic pain and other CNS disorders. The company was spun out of proprietary R&D programmes from the CRO NiKem Research in April 2007.